AR044450A1 - Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas - Google Patents

Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas

Info

Publication number
AR044450A1
AR044450A1 ARP040101846A ARP040101846A AR044450A1 AR 044450 A1 AR044450 A1 AR 044450A1 AR P040101846 A ARP040101846 A AR P040101846A AR P040101846 A ARP040101846 A AR P040101846A AR 044450 A1 AR044450 A1 AR 044450A1
Authority
AR
Argentina
Prior art keywords
dependent diseases
prophylaxis
treatment
composition
hormone dependent
Prior art date
Application number
ARP040101846A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Jens Hoffmann
Martin Schneider
Gerhard Siemeister
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33450989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044450(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR044450A1 publication Critical patent/AR044450A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos y usos para prevenir o tratar enfermedades dependientes de hormonas, en particular cáncer de mama, en un mamífero, mediante una combinación de un antagonista de receptores de progesterona, (11b-(4-acetil-fenil)-17b-hidroxi-17a-(1,1,2,2,2- pentafluoroetil)-estra-4,9-dien-3-ona o un derivado o análogo del mismo aceptable para uso farmacéutico), y un antiestrógeno puro, (11b-fluoro-17a-metil-7a-{5-[metil(8,8,9,9,9-pentafluorononil)amino]pentil}-estra-1,3,5(10)-trien-3,17b-diol, entre otros) y composiciones farmacéuticas que comprenden dicha combinación.
ARP040101846A 2003-05-28 2004-05-28 Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas AR044450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/446,165 US20040242551A1 (en) 2003-05-28 2003-05-28 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Publications (1)

Publication Number Publication Date
AR044450A1 true AR044450A1 (es) 2005-09-14

Family

ID=33450989

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101846A AR044450A1 (es) 2003-05-28 2004-05-28 Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas

Country Status (18)

Country Link
US (3) US20040242551A1 (es)
EP (2) EP1834644A3 (es)
JP (1) JP2006528226A (es)
KR (1) KR20060005412A (es)
CN (1) CN1893955A (es)
AR (1) AR044450A1 (es)
AU (1) AU2004243500A1 (es)
BR (1) BRPI0410707A (es)
CA (1) CA2524750A1 (es)
CL (1) CL2004001317A1 (es)
EA (1) EA011506B1 (es)
MX (1) MXPA05012841A (es)
NO (1) NO20056153L (es)
PE (1) PE20050207A1 (es)
TW (1) TW200505936A (es)
UY (1) UY28334A1 (es)
WO (1) WO2004105768A1 (es)
ZA (1) ZA200510449B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
CA2528433A1 (en) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
CA2683809A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen
PL2983671T4 (pl) * 2013-04-11 2019-04-30 Bayer Pharma AG Postać dawkowania antagonisty receptora progesteronowego
CN117534720A (zh) * 2022-08-01 2024-02-09 香港中文大学（深圳） 环戊烷多氢菲衍生物及其制备方法和应用
CN115505019B (zh) * 2022-11-07 2024-01-26 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36654A (en) * 1970-04-24 1974-07-31 Ciba Geigy Ag 3-cyclopentyl ethers of 7alpha-methyl-3,16alpha,17(alpha and beta)-trihydroxy-delta 1,3,5(10)-estratriene,their manufacture and estrogenic pharmaceutical compositions containing them
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE19622457A1 (de) * 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE19807791A1 (de) * 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
SK4702003A3 (en) * 2000-10-18 2004-01-08 Schering Ag Use of antiprogestins for the induction of apoptosis in a cell
CA2423017C (en) * 2000-10-18 2009-01-06 Bayer Schering Pharma Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
PE20050207A1 (es) 2005-04-28
CL2004001317A1 (es) 2005-05-06
US20050014736A1 (en) 2005-01-20
EA011506B1 (ru) 2009-04-28
EP1834644A2 (en) 2007-09-19
MXPA05012841A (es) 2006-02-13
US20040242551A1 (en) 2004-12-02
EP1628669A1 (en) 2006-03-01
JP2006528226A (ja) 2006-12-14
AU2004243500A1 (en) 2004-12-09
BRPI0410707A (pt) 2006-06-13
CA2524750A1 (en) 2004-12-09
UY28334A1 (es) 2004-12-31
US20070238714A1 (en) 2007-10-11
CN1893955A (zh) 2007-01-10
WO2004105768A1 (en) 2004-12-09
EA200501739A1 (ru) 2006-06-30
WO2004105768A8 (en) 2006-04-06
TW200505936A (en) 2005-02-16
ZA200510449B (en) 2007-04-25
EP1834644A3 (en) 2007-11-07
NO20056153L (no) 2006-02-22
KR20060005412A (ko) 2006-01-17

Similar Documents

Publication Publication Date Title
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BRPI0516243C1 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
CL2012000166A1 (es) Compuesto (11beta,17beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; y su uso para el tratamiento y/o la prevencion de fibroides uterinos, endometriosis, sangrados menstruales severos, meningiomas, cancer de mama hormonodependiente y de trastornos asociados a la menopausia, entre otros.
PE20060485A1 (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
EE05259B1 (et) Antiprogestiinide kasutamine hormoons?ltuvate haiguste proflaktikaks ja raviks
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
TN2017000482A1 (en) Selective progesterone receptor modulator (sprm) regimen.
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
ES2543836T3 (es) Procedimientos y composiciones para el tratamiento de afecciones miocárdicas
IS2702B (is) Notkun á (11beta, 17beta)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón í meðhöndluninni á alvarlegri geðdeyfðartruflun
AR066231A1 (es) Combinacion de antagonista del receptor de progesterona con atiestrogenos no esteroidales para usar en enfermedades mediadas por brca (genes supresores de tumores)
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
NO20072687L (no) Farmasoytisk prevensjonspreparat
AR044095A1 (es) Composicion farmaceutica que comprende un antagonista del receptor de la hormona del crecimiento y un antihipertensivo y uso de los mismos para prepararla
AR032371A1 (es) Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
DOP2005000278A (es) Composiciones farmaceuticas solidas que comprenden una combinacion de drospirenon, etinilestradiol y un agente surfactante adecuado que presentan una homogeneidad de contend y velocidad de dosolucion asegurada para la droga no micronizada, procedomiento para prepara dicha composicion y uso de esta composicion para preparar un medicamento.
CO6150137A2 (es) Composicion farmaceutica que contiene bicalutamida y un metodo para su uso
ECSP003820A (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
PE20091020A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
TW200733955A (en) Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
TH58099A (th) การใช้ และสารผสมแอนติโปรเจสตินในการรักษาโรคต่อมลูกหมาก
PE20040402A1 (es) Procedimientos para reducir la incidencia de cerdos mortinatos mediante el uso de antagonistas del receptor de la progesterona

Legal Events

Date Code Title Description
FB Suspension of granting procedure